کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6140035 | 1594246 | 2014 | 7 صفحه PDF | دانلود رایگان |
- We generated a mouse monoclonal antibody that neutralized chikungunya virus.
- Post-infection treatment with MAb resulted in reduced plaque size.
- The antibody recognized E1 and inhibited virus release.
Chikungunya virus (CHIKV) causes an acute clinical illness characterized by sudden high fever, intense joint pain, and skin rash. Recent outbreaks of chikungunya disease in Africa and Asia are a major public health concern; however, there is currently no effective licensed vaccine or specific treatment. This study reported the development of a mouse monoclonal antibody (MAb), CK47, which recognizes domain III within the viral envelope 1 protein and inhibited the viral release process, thereby preventing the production of progeny virus. The MAb had no effect on virus entry and replication processes. Thus, CK47 may be a useful tool for studying the mechanisms underlying CHIKV release and may show potential as a therapeutic agent.
Journal: Virology - Volumes 464â465, September 2014, Pages 111-117